Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)

Simply Wall St.12-04

It's not a stretch to say that Neogen Corporation's (NASDAQ:NEOG) price-to-sales (or "P/S") ratio of 3.3x right now seems quite "middle-of-the-road" for companies in the Medical Equipment industry in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488335321?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2024-12-04 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488335321","market":"sg","top_or_hot":-1,"title":"Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)","media":"Simply Wall St.","content":"<div>\n<p>It's not a stretch to say that Neogen Corporation's  (NASDAQ:NEOG) price-to-sales (or \"P/S\") ratio of 3.3x right now seems quite \"middle-of-the-road\" for companies in the Medical Equipment industry in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-417\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRisks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 02:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-417><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's not a stretch to say that Neogen Corporation's  (NASDAQ:NEOG) price-to-sales (or \"P/S\") ratio of 3.3x right now seems quite \"middle-of-the-road\" for companies in the Medical Equipment industry in...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-417\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SQQQ","symbol_name":"纳指三倍做空ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/risks-to-shareholder-returns-are-elevated-at-these-prices-fo-417","article_id":"2488335321","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488335321","pubTimestamp":1733252066,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or \"P/S\") ratio of 3.3x right now...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","TQQQ":"纳指三倍做多ETF","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4198":"医疗保健用品",".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2211817866.USD":"Allianz Food Security AT Acc USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","PSQ":"纳指反向ETF","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NEOG":"纽尔真检测","BK4112":"金融交易所和数据"},"translate_title":"Neogen Corporation（纳斯达克股票代码：NEOG）的股东回报风险在这些价格下会增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"It's not a stretch to say that Neogen Corporation's  (NASDAQ:NEOG) price-to-sales (or \"P/S\") ratio of 3.3x right now seems quite \"middle-of-the-road\" for companies in the Medical Equipment industry in the United States, where the median P/S ratio is around 3.4x.  However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.      Check out our latest analysis for Neogen NasdaqGS:NEOG Price to Sales Ratio vs Industry December 3rd 2024 How Neogen Has Been Performing  Neogen could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth.   Perhaps the market is expecting its poor revenue performance to improve, keeping the P/S from dropping.  If not, then existing shareholders may be a little nervous about the viability of the share price.     Keen to find out how analysts think Neogen's future stacks up against the industry? In that case, our free report is a great place to start.  Do Revenue Forecasts Match The P/S Ratio?   There's an inherent assumption that a company should be matching the industry for P/S ratios like Neogen's to be considered reasonable.   If we review the last year of revenue, the company posted a result that saw barely any deviation from a year ago.   However, a few strong years before that means that it was still able to grow revenue by an impressive 87% in total over the last three years.  Accordingly, shareholders will be pleased, but also have some questions to ponder about the last 12 months.     Looking ahead now, revenue is anticipated to climb by 3.9% during the coming year according to the dual analysts following the company.  That's shaping up to be materially lower than the 9.1% growth forecast for the broader industry.  With this information, we find it interesting that Neogen is trading at a fairly similar P/S compared to the industry.  It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock.  Maintaining these prices will be difficult to achieve as this level of revenue growth is likely to weigh down the shares eventually.    The Bottom Line On Neogen's P/S  Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.  Given that Neogen's revenue growth projections are relatively subdued in comparison to the wider industry, it comes as a surprise to see it trading at its current P/S ratio.  At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long.  A positive change is needed in order to justify the current price-to-sales ratio.      A lot of potential risks can sit within a company's balance sheet.  You can assess many of the main risks through our free balance sheet analysis for Neogen with six simple checks.   If these risks are making you reconsider your opinion on Neogen, explore our interactive list of high quality stocks to get an idea of what else is out there. Valuation is complex, but we're here to simplify it.Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488335321"}